Cardiff Oncology (NASDAQ:CRDF) Issues Quarterly Earnings Results
Cardiff Oncology (NASDAQ:CRDF) reported quarterly earnings of ($0.17) per share, exceeding the consensus estimate of ($0.20) by $0.03. The company has a negative net margin of 9,344.14% and a negative return on equity of 77.94%. The stock traded up 0.4% to $2.25, with an average target price of $10.63. Analysts have mixed ratings, with four Buy, one Hold, and one Sell. Institutional investors have increased their stakes in the company, which focuses on developing therapies for various cancers.
Cardiff Oncology (NASDAQ:CRDF - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03, Zacks reports. Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 77.94%.
Get Cardiff Oncology alerts:
Cardiff Oncology Trading Up 0.4%
CRDF traded up $0.01 during trading on Thursday, hitting $2.25. 612,673 shares of the company traded hands, compared to its average volume of 762,118. The company has a market cap of $149.69 million, a PE ratio of -2.59 and a beta of 1.68. The stock's 50-day simple moving average is $2.17 and its two-hundred day simple moving average is $2.80. Cardiff Oncology has a 1 year low of $1.90 and a 1 year high of $5.64.
Analysts Set New Price Targets
Several research firms have weighed in on CRDF. HC Wainwright decreased their price target on shares of Cardiff Oncology from $18.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Cardiff Oncology in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.63.
Check Out Our Latest Stock Report on Cardiff Oncology
Hedge Funds Weigh In On Cardiff Oncology
Several institutional investors have recently bought and sold shares of CRDF. Geode Capital Management LLC grew its stake in shares of Cardiff Oncology by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company's stock worth $4,723,000 after buying an additional 104,409 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Cardiff Oncology by 189.3% in the 2nd quarter. Bank of America Corp DE now owns 93,393 shares of the company's stock worth $294,000 after buying an additional 61,110 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Cardiff Oncology by 34.2% in the 2nd quarter. Rhumbline Advisers now owns 84,759 shares of the company's stock worth $267,000 after buying an additional 21,617 shares in the last quarter. Glenview Trust co grew its stake in shares of Cardiff Oncology by 79.9% in the 2nd quarter. Glenview Trust co now owns 43,128 shares of the company's stock worth $136,000 after buying an additional 19,150 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Cardiff Oncology by 50.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company's stock worth $108,000 after buying an additional 11,497 shares in the last quarter. 16.29% of the stock is owned by hedge funds and other institutional investors.
About Cardiff Oncology
(Get Free Report)Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Further Reading
- Five stocks we like better than Cardiff Oncology
- Russell 2000 Index, How Investors Use it For Profitable Trading
- CAVA Stock Looking for Direction After Earnings Miss
- Manufacturing Stocks Investing
- 3 Small AI Stocks Ready to Explode (All Under $20)
- Large Cap Stock Definition and How to Invest
- After 16% Fall, Analysts Eye a Big Recovery in Meta Platforms
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Cardiff Oncology Right Now?
Before you consider Cardiff Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiff Oncology wasn't on the list.
While Cardiff Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
